Evidence map›Paper›PMID 39042245›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2024

Performance assessment of a new serological diagnostic test for COVID-19 with candidate peptides from spike and nucleocapsid viral proteins.

Vanessa de Melo Cavalcanti-Dantas, Alan Frazão da Silva, Andrei Félix Mendes, Waldecir Oliveira de Araújo Júnior, Lucas Coêlho Bernardo-Menezes, Cristiane Campello Bresani-Salvi, Lúcio Roberto Cançado Castellano, Ana Isabel Vieira Fernandes, Sherlan Guimarães Lemos, Jurandy Júnior Ferraz de Magalhães and 4 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Vanessa de Melo Cavalcanti-DantasLaboratory of Virology and Experimental Therapy, Department of Virology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Recife, Pernambuco, Brazil.
Alan Frazão da SilvaLaboratory of Experimental Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Andrei Félix MendesLaboratory of Microbiology, Department of Microbiology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Recife, Pernambuco, Brazil.
Waldecir Oliveira de Araújo JúniorLaboratory of Immunology and Hematology, Department of Physiology and Pathology, Multidisciplinary Research Group in Biotechnology and Health (GePeMBiS), Federal University of Paraiba, João Pessoa, Paraíba, Brazil.
Lucas Coêlho Bernardo-MenezesLaboratory of Virology and Experimental Therapy, Department of Virology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Recife, Pernambuco, Brazil.
Cristiane Campello Bresani-SalviLaboratory of Virology and Experimental Therapy, Department of Virology, Group of Integrated Studies in Nutrition and Health, Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Instituto de Medicina Integral Prof Fernando Figueira, Recife, Pernambuco, Brazil.
Lúcio Roberto Cançado CastellanoProfessional and Technological Center of the Technical School of Health, Federal University of Paraiba, João Pessoa, Paraíba, Brazil.
Ana Isabel Vieira FernandesHealth Promotion Department of the Medical Sciences Center and Division for Infectious and Parasitic Diseases, Lauro Wanderley University Hospital, Federal University of Paraiba, João Pessoa, Paraíba, Brazil.
Sherlan Guimarães LemosAdvanced Study Group in Analytical Chemistry, Department of Chemistry, Federal University of Paraiba, João Pessoa, Paraíba, Brazil.
Jurandy Júnior Ferraz de MagalhãesLaboratory of Virology and Experimental Therapy, Department of Virology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Recife, Pernambuco, Brazil.
Renato Antônio Dos Santos OliveiraLaboratory of Immunology and Hematology, Department of Physiology and Pathology, Multidisciplinary Research Group in Biotechnology and Health (GePeMBiS), Federal University of Paraiba, João Pessoa, Paraíba, Brazil.
Priscilla Anne Castro de AssisLaboratory of Immunology and Hematology, Department of Physiology and Pathology, Multidisciplinary Research Group in Biotechnology and Health (GePeMBiS), Federal University of Paraiba, João Pessoa, Paraíba, Brazil.
Joelma Rodrigues de Souza *Laboratory of Immunology and Hematology, Department of Physiology and Pathology, Multidisciplinary Research Group in Biotechnology and Health (GePeMBiS), Federal University of Paraiba, João Pessoa, Paraíba, Brazil.
Clarice Neuenschwander Lins de Morais *Laboratory of Virology and Experimental Therapy, Department of Virology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Recife, Pernambuco, Brazil. clarice.lins@fiocruz.br.ORCID http://orcid.org/0000-0002-0887-8163

Funding

Centro de Pesquisas Aggeu Magalhães, Fundação Oswaldo Cruz VPPCB-005-FIO-20-2-22Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) APQ-03613-17Fundação de Amparo a Ciência e Tecnologia de Pernambuco APQ-0396-2.11/20Fundação de Apoio à Pesquisa do Estado da Paraíba 003/2020Fundação de Apoio à Pesquisa do Estado da Paraíba 071/2020
6 · The paper itself

Abstract

Numerous commercial tests for the serological diagnosis of COVID-19 have been produced in recent years. However, it is important to note that these tests exhibit significant variability in their sensitivity, specificity, and accuracy of results. Therefore, the objective of this study was to utilize bioinformatics tools to map SARS-CoV-2 peptides, with the goal of developing a new serological diagnostic test for COVID-19. Two peptides from the S protein and one from the N protein were selected and characterized in silico, chemically synthesized, and used as a serological diagnostic tool to detect IgM, IgG, and IgA anti-SARS-CoV-2 antibodies through the ELISA technique, confirmed as positive and negative samples by RT-qPCR or serology by ELISA. The results showed a sensitivity, specificity, Positive Predictive Value and Negative Predictive Value of 100% (p < 00001, 95% CI) for the proposed test. Although preliminary, this study brings proof-of-concept results that are consistent with the high-performance rates of the ELISA test when compared to other well-established methods for diagnosing COVID-19.

Indexed as

Antibodies, ViralCoronavirus Nucleocapsid ProteinsCOVID-19COVID-19 Serological TestingEnzyme-Linked Immunosorbent AssaySARS-CoV-2Sensitivity and SpecificitySpike Glycoprotein, CoronavirusComputational BiologyHumansImmunoglobulin GImmunoglobulin MPeptidesPhosphoproteinsAntibodies, ViralCoronavirus Nucleocapsid ProteinsImmunoglobulin GImmunoglobulin Mnucleocapsid phosphoprotein, SARS-CoV-2PeptidesPhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2CoronavirusDiagnosisEpitopesSerology

Identifiers

PMID39042245
PMCPMC11405565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.